市場調査レポート

商品コード

欧州のT細胞療法：2030年までの市場予測 - 地域別分析 - モダリティ別、治療タイプ別、適応症別

Europe T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

出版日: 2024年01月15日 | 発行: The Insight Partners

| ページ情報: 英文 78 Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 3,550 557,847円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 4,550 714,987円

レポートPDFを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 5,550 872,127円

レポートPDFを企業内すべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

欧州のT細胞療法市場は、2022年に6億9,924万米ドルと評価され、2030年には23億4,549万米ドルに達すると予測され、2022年から2030年までのCAGRは16.3%で成長すると推定されます。

T細胞療法の承認件数の増加が欧州のT細胞療法市場を牽引

標的を絞った治療、より迅速で効率的な回復、副作用の軽減などがT細胞療法の利点です。世界的に細胞療法が広く採用されているのは、さまざまな承認が得られているからです。例えば

2023年欧州委員会は、CD19指向性キメラ抗原受容体（CAR）T細胞療法であるBreyanzi（lisocabtagene maraleucel;liso-cel）を承認しました。CAR T細胞療法に見られる4-1BBコスティミュレイトリー・ドメインは、CAR T細胞の拡大と持続性を増強します。高悪性度B細胞リンパ腫（HGBCL）、びまん性大細胞型B細胞リンパ腫（DLBCL）、原発性縦隔大細胞型B細胞リンパ腫（PMBCL）、濾胞性リンパ腫グレード3B（FL3B）で、一次化学療法に不応の成人、または治療終了後1年以内に再発した成人がこの治療の対象となります。

2022年：欧州医薬品委員会（CHMP）の承認により、アタラ・バイオセラピューティクス社のエブバロは、世界で初めて認可された同種T細胞療法となります。

2022年：ギリアド社傘下のカイト社は、イエスカルタ（アキシカブタジェン・シロロイセル）が、一次化学療法に不応または終了後1年以内に再発した高悪性度B細胞リンパ腫（HGBL）およびびまん性大細胞型B細胞リンパ腫（DLBCL）の成人患者に対する治療薬として欧州委員会から承認されたと発表しました。

このように、T細胞療法の承認件数の増加が市場の成長を後押ししています。

欧州のT細胞療法市場概要

欧州のT細胞療法市場は、ドイツ、英国、フランス、イタリア、スペイン、その他欧州に区分されます。ドイツや英国などの国々は、この地域の市場に対する最大の貢献国になると予想されます。血液悪性腫瘍や固形がんの有病率の上昇と、それに伴うT細胞療法の承認増加が、欧州の市場成長を促進する主な要因です。

国民保健サービス（NHS）によると、英国では毎年800人が急性リンパ芽球性白血病と診断され、毎年5,500人がB細胞リンパ腫と診断されています。英国では白血病とリンパ腫が多いため、人々はこれらのがんを治療するためにT細胞療法を選択しています。T細胞療法の認知度と肯定的な結果を受け、NHSは個別化CAR T細胞療法へのアクセスを拡大するため、アストラゼネカなど様々な企業と契約を結んでいます。

欧州のT細胞療法市場の収益と2030年までの予測（US$Mn）

欧州のT細胞療法市場のセグメンテーション

欧州のT細胞療法市場は、モダリティ、治療タイプ、適応症、国別に区分されます。

モダリティに基づき、欧州のT細胞療法市場は研究と商業化に二分されます。2022年の市場シェアは、商業化されたセグメントの方が大きいです。

治療タイプに基づき、欧州のT細胞療法市場はCAR T細胞療法とT細胞受容体（TCR）ベースに分けられます。2022年の市場シェアはCAR T細胞療法が上回った。

適応症に基づくと、欧州のT細胞療法市場は血液悪性腫瘍と固形腫瘍に二分されます。2022年には血液悪性腫瘍分野が最大の市場シェアを占めました。

国別では、欧州のT細胞療法市場はドイツ、英国、フランス、イタリア、スペイン、その他欧州に区分されます。2022年の欧州のT細胞療法市場はドイツが支配的でした。

Bristol-Myers Squibb Co、Gilead Sciences Inc、Immunocore Holdings Plc、Innovent Biologics Inc、Janssen Global Services LLC、Legend Biotech Corp、Novartis AGは、欧州のT細胞療法市場で事業を展開する大手企業の一部です。

List Of Tables

Table 1. Europe T Cell Therapy Market Segmentation
Table 2. Europe T Cell Therapy Market, by Hematological Malignancies - Revenue and Forecast to 2030 (US$ Million)
Table 3. UK Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 4. UK Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 5. UK Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 6. UK Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 7. Germany: Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 8. Germany: Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 9. Germany: Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 10. Germany: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 11. France: Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 12. France: Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. France: Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 14. France: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 15. Italy: Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 16. Italy: Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 17. Italy: Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 18. Italy: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 19. Spain: Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain: Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 21. Spain: Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 22. Spain: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Europe T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 24. Rest of Europe T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 25. Rest of Europe T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 26. Rest of Europe T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 27. Recent Organic Growth Strategies in Europe T Cell Therapy Market
Table 28. Recent Inorganic Growth Strategies in the Europe T Cell Therapy Market
Table 29. Glossary of Terms, Europe T Cell Therapy Market

List Of Figures

Figure 1. Europe T Cell Therapy Market Segmentation, By Country
Figure 2. Europe T Cell Therapy Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Europe T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 6. Research: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Commercialized: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Europe T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 9. CAR T-cell Therapy: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. T-cell Receptor (TCR)-based: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Europe T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 12. Hematologic Malignancies: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Solid Tumor: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Europe T Cell Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
Figure 15. Europe T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 16. UK Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Germany: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. France: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Italy: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. Spain: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Growth Strategies in T Cell Therapy Market

Product Code: BMIRE00029308

The Europe T cell therapy market was valued at US$ 699.24 million in 2022 and is expected to reach US$ 2,345.49 million by 2030; it is estimated to grow at a CAGR of 16.3% from 2022 to 2030.

Increasing Number of T-Cell Therapy Approvals Drives the Europe T Cell Therapy Market

Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approvals. For instance,

In 2023: The European Commission has granted approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. A 4-1BB costimulatory domain found in CAR T-cell therapy augments the expansion and persistence of CAR T cells. Adults with high grade B-cell lymphoma (HGBCL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) who are refractory to first-line chemotherapy or who relapsed within a year of finishing treatment are eligible for this treatment.

In 2022: With approval from the European Committee for Medicinal Products for Human Use (CHMP), Ebvallo from Atara Biotherapeutics is set to become the world's first licensed allogeneic T-cell therapy.

In 2022: Kite, a Gilead Company, announced that Yescarta (axicabtagene ciloleucel) has been approved by the European Commission for the treatment of adult patients with high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL) who are refractory to first-line chemotherapy or who relapse within a year of finishing it.

Thus, the increasing number of approvals for T-cell therapy is fueling the market growth.

Europe T Cell Therapy Market Overview

The European T-cell therapy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Countries such as Germany and the UK are expected to be the largest contributors to the market in this region. The rising prevalence of hematologic malignancies and solid tumors and the subsequent rise in approval of T-cell therapy are the major factors driving the market growth in Europe.

According to National Health Service (NHS), ~800 people in the UK are diagnosed with acute lymphoblastic leukemia yearly, and ~ 5,500 people in England are diagnosed with B-cell lymphoma annually. Due to the prevalence of leukemia and lymphoma in the UK, people opt for T-cell therapy to treat these cancers. Owing to the awareness and positive results of T-cell therapies, NHS has struck deals with various companies, such as AstraZeneca, to expand access to personalized CAR T-cell therapies.

Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

Europe T Cell Therapy Market Segmentation

The Europe T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the Europe T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the Europe T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the Europe T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the Europe T cell therapy market is segmented into Germany, UK, France, Italy, Spain, the Rest of Europe. Germany dominated the Europe T cell therapy market in 2022.

Bristol-Myers Squibb Co, Gilead Sciences Inc, Immunocore Holdings Plc, Innovent Biologics Inc, Janssen Global Services LLC, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Europe T cell therapy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Europe T Cell Therapy Market, by Country (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe T Cell Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Growing Burden of Cancer Worldwide
- 4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
- 4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
- 4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
- 4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:

5. T Cell Therapy Market - Europe Market Analysis

5.1 Europe T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

6. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

6.1 Overview
6.2 Europe T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
- 6.3.1 Overview
- 6.3.2 Research: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
- 6.4.1 Overview
- 6.4.2 Commercialized: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

7.1 Overview
7.2 Europe T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
- 7.3.1 Overview
- 7.3.2 CAR T-cell Therapy: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
- 7.4.1 Overview
- 7.4.2 T-cell Receptor (TCR)-based: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

8.1 Overview
8.2 Europe T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
- 8.3.1 Overview
- 8.3.2 Hematologic Malignancies: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.3 Europe T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
- 8.4.1 Overview
- 8.4.2 Solid Tumor: Europe T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe T Cell Therapy Market - Country Analysis

9.1 Europe

10. T Cell Therapy Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Immunocore Holdings Plc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Legend Biotech Corp
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Janssen Global Services LLC
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Gilead Sciences Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Bristol-Myers Squibb Co
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Novartis AG
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Innovent Biologics Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

欧州のT細胞療法：2030年までの市場予測 - 地域別分析 - モダリティ別、治療タイプ別、適応症別

Europe T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章欧州のT細胞療法市場：主要産業力学

第5章 T細胞療法市場：欧州市場分析

第6章欧州のT細胞療法市場：収益と2030年までの予測 - モダリティ別

第7章欧州のT細胞療法市場：収益と2030年までの予測 - 治療タイプ別

第8章欧州のT細胞療法市場：収益と2030年までの予測 - 適応症別

第9章欧州のT細胞療法市場：国別分析

第10章 T細胞療法市場-業界情勢

第11章企業プロファイル

第12章付録

List Of Tables

List Of Figures

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Europe T Cell Therapy Market - Key Industry Dynamics

5. T Cell Therapy Market - Europe Market Analysis

6. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

7. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

8. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

9. Europe T Cell Therapy Market - Country Analysis

10. T Cell Therapy Market-Industry Landscape

11. Company Profiles

12. Appendix

欧州のT細胞療法：2030年までの市場予測 - 地域別分析 - モダリティ別、治療タイプ別、適応症別

Europe T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 欧州のT細胞療法市場：主要産業力学

第5章 T細胞療法市場：欧州市場分析

第6章 欧州のT細胞療法市場：収益と2030年までの予測 - モダリティ別

第7章 欧州のT細胞療法市場：収益と2030年までの予測 - 治療タイプ別

第8章 欧州のT細胞療法市場：収益と2030年までの予測 - 適応症別

第9章 欧州のT細胞療法市場：国別分析

第10章 T細胞療法市場-業界情勢

第11章 企業プロファイル

第12章 付録

List Of Tables

List Of Figures

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Europe T Cell Therapy Market - Key Industry Dynamics

5. T Cell Therapy Market - Europe Market Analysis

6. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

7. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

8. Europe T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

9. Europe T Cell Therapy Market - Country Analysis

10. T Cell Therapy Market-Industry Landscape

11. Company Profiles

12. Appendix

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章欧州のT細胞療法市場：主要産業力学

第6章欧州のT細胞療法市場：収益と2030年までの予測 - モダリティ別

第7章欧州のT細胞療法市場：収益と2030年までの予測 - 治療タイプ別

第8章欧州のT細胞療法市場：収益と2030年までの予測 - 適応症別

第9章欧州のT細胞療法市場：国別分析

第11章企業プロファイル

第12章付録